ACIU:NSD-AC Immune Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.37

Change

0.00 (0.00)%

Market Cap

USD 0.28B

Volume

0.02M

Avg Analyst Target

USD 16.00 (+374.78%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACIU Stock Forecast & Price:
Based on the AC Immune Ltd stock forecasts from 1 analysts, the average analyst target price for AC Immune Ltd is USD 16.00 over the next 12 months. AC Immune Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AC Immune Ltd is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, AC Immune Ltd’s stock price was USD 3.37. AC Immune Ltd’s stock price has changed by -0.59% over the past week, +2.74% over the past month and -59.59% over the last year.

About AC Immune Ltd (ACIU:NSD)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

N/A

USD65.40B 8.39 6.52
MRNA Moderna Inc

N/A

USD59.64B 4.20 2.94
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.28B 2.86 1.54
SGEN Seagen Inc

N/A

USD33.15B 55.02 -50.53
RPRX Royalty Pharma Plc

N/A

USD28.81B 29.89 16.26
GMAB Genmab AS

N/A

USD21.88B 64.29 5.76
ARGX argenx NV ADR

N/A

USD20.61B N/A -30.89
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACIU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.92% 67% D+ 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.92% 67% D+ 41% F
Trailing 12 Months  
Capital Gain -59.59% 57% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.59% 57% F 30% F
Trailing 5 Years  
Capital Gain -61.70% 47% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.70% 47% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -9.24% 38% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.24% 38% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 39.10% 70% C- 39% F
Risk Adjusted Return -23.63% 36% F 28% F
Market Capitalization 0.28B 65% D 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.63 43% F 63% D
Price/Book Ratio 1.27 63% D 62% D-
Price / Cash Flow Ratio -4.28 63% D 70% C-
EV/EBITDA -1.45 59% F 69% D+
Management Effectiveness  
Return on Equity -35.63% 72% C- 29% F
Return on Invested Capital -35.32% 69% D+ 26% F
Return on Assets -21.74% 62% D- 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.32 44% F 31% F
Short Percent 1.16% 80% B- 73% C
Beta 0.86 76% C 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector